Figshareopen access
Cost-effectiveness analysis of anlotinib plus penpulimab as first-line treatment for unresectable hepatocellular carcinoma
medicine, pharmacology, sociology, science policy, biological sciences not elsewhere classified, cost-effectiveness, anlotinib, penpulimab
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗Related documents
Record · ID 460274
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.